Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.

Autor:	Joshi I; Development and Regulatory Department, Partner Therapeutics, Inc., Lexington, MA, United States., Carney WP; Walt Carney Biomarkers Consulting, LLC., North Andover, MA, United States., Rock EP; Development and Regulatory Department, Partner Therapeutics, Inc., Lexington, MA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Feb 07; Vol. 14, pp. 1130214. Date of Electronic Publication: 2023 Feb 07 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1130214
Abstrakt:	Sepsis, a heterogeneous clinical syndrome, features a systemic inflammatory response to tissue injury or infection, followed by a state of reduced immune responsiveness. Measurable alterations occur in both the innate and adaptive immune systems. Immunoparalysis, an immunosuppressed state, associates with worsened outcomes, including multiple organ dysfunction syndrome, secondary infections, and increased mortality. Multiple immune markers to identify sepsis immunoparalysis have been proposed, and some might offer clinical utility. Sepsis immunoparalysis is characterized by reduced lymphocyte numbers and downregulation of class II human leukocyte antigens (HLA) on innate immune monocytes. Class II HLA proteins present peptide antigens for recognition by and activation of antigen-specific T lymphocytes. One monocyte class II protein, mHLA-DR, can be measured by flow cytometry. Downregulated mHLA-DR indicates reduced monocyte responsiveness, as measured by ex-vivo cytokine production in response to endotoxin stimulation. Our literature survey reveals low mHLA-DR expression on peripheral blood monocytes correlates with increased risks for infection and death. For mHLA-DR, 15,000 antibodies/cell appears clinically acceptable as the lower limit of immunocompetence. Values less than 15,000 antibodies/cell are correlated with sepsis severity; and values at or less than 8000 antibodies/cell are identified as severe immunoparalysis. Several experimental immunotherapies have been evaluated for reversal of sepsis immunoparalysis. In particular, sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF), has demonstrated clinical benefit by reducing hospitalization duration and lowering secondary infection risk. Lowered infection risk correlates with increased mHLA-DR expression on peripheral blood monocytes in these patients. Although mHLA-DR has shown promising utility for identifying sepsis immunoparalysis, absence of a standardized, analytically validated method has thus far prevented widespread adoption. A clinically useful approach for patient inclusion and identification of clinically correlated output parameters could address the persistent high unmet medical need for effective targeted therapies in sepsis. Competing Interests: IJ is an employee of and has stock options for Partner Therapeutics, Inc. WPC is the owner of Walt Carney Biomarkers Consulting and a paid consultant for Partner Therapeutics, Inc. At the time of the drafting of this manuscript, EPR was an employee of Partner Therapeutics, Inc. and has stock options. (Copyright © 2023 Joshi, Carney and Rock.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu